A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol
Background Postoperative thyroid stimulating hormone (TSH) suppression therapy is recommended for patients with intermediate- and high-risk differentiated thyroid cancer to prevent the recurrence of thyroid cancer. With the recent increase in small thyroid cancer cases, the extent of resection durin...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Academya Publishing Co.
2021-06-01
|
Series: | Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://www.e-enm.org/upload/pdf/enm-2020-943.pdf |
id |
doaj-21d56038b3d5450bb69611762dcf6f10 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Eun Kyung Lee Yea Eun Kang Young Joo Park Bon Seok Koo Ki-Wook Chung Eu Jeong Ku Ho-Ryun Won Won Sang Yoo Eonju Jeon Se Hyun Paek Yong Sang Lee Dong Mee Lim Yong Joon Suh Ha Kyoung Park Hyo-Jeong Kim Bo Hyun Kim Mijin Kim Sun Wook Kim Ka Hee Yi Sue K. Park Eun-Jae Jung June Young Choi Ja Seong Bae Joon Hwa Hong Kee-Hyun Nam Young Ki Lee Hyeong Won Yu Sujeong Go Young Mi Kang |
spellingShingle |
Eun Kyung Lee Yea Eun Kang Young Joo Park Bon Seok Koo Ki-Wook Chung Eu Jeong Ku Ho-Ryun Won Won Sang Yoo Eonju Jeon Se Hyun Paek Yong Sang Lee Dong Mee Lim Yong Joon Suh Ha Kyoung Park Hyo-Jeong Kim Bo Hyun Kim Mijin Kim Sun Wook Kim Ka Hee Yi Sue K. Park Eun-Jae Jung June Young Choi Ja Seong Bae Joon Hwa Hong Kee-Hyun Nam Young Ki Lee Hyeong Won Yu Sujeong Go Young Mi Kang A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol Endocrinology and Metabolism thyroid neoplasms thyrotropin thyroxine recurrence thyroidectomy |
author_facet |
Eun Kyung Lee Yea Eun Kang Young Joo Park Bon Seok Koo Ki-Wook Chung Eu Jeong Ku Ho-Ryun Won Won Sang Yoo Eonju Jeon Se Hyun Paek Yong Sang Lee Dong Mee Lim Yong Joon Suh Ha Kyoung Park Hyo-Jeong Kim Bo Hyun Kim Mijin Kim Sun Wook Kim Ka Hee Yi Sue K. Park Eun-Jae Jung June Young Choi Ja Seong Bae Joon Hwa Hong Kee-Hyun Nam Young Ki Lee Hyeong Won Yu Sujeong Go Young Mi Kang |
author_sort |
Eun Kyung Lee |
title |
A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol |
title_short |
A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol |
title_full |
A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol |
title_fullStr |
A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol |
title_full_unstemmed |
A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol |
title_sort |
multicenter, randomized, controlled trial for assessing the usefulness of suppressing thyroid stimulating hormone target levels after thyroid lobectomy in low to intermediate risk thyroid cancer patients (master): a study protocol |
publisher |
Academya Publishing Co. |
series |
Endocrinology and Metabolism |
issn |
2093-596X 2093-5978 |
publishDate |
2021-06-01 |
description |
Background Postoperative thyroid stimulating hormone (TSH) suppression therapy is recommended for patients with intermediate- and high-risk differentiated thyroid cancer to prevent the recurrence of thyroid cancer. With the recent increase in small thyroid cancer cases, the extent of resection during surgery has generally decreased. Therefore, questions have been raised about the efficacy and long-term side effects of TSH suppression therapy in patients who have undergone a lobectomy. Methods This is a multicenter, prospective, randomized, controlled clinical trial in which 2,986 patients with papillary thyroid cancer are randomized into a high-TSH group (intervention) and a low-TSH group (control) after having undergone a lobectomy. The principle of treatment includes a TSH-lowering regimen aimed at TSH levels between 0.3 and 1.99 μIU/mL in the low-TSH group. The high-TSH group targets TSH levels between 2.0 and 7.99 μIU/mL. The dose of levothyroxine will be adjusted at each visit to maintain the target TSH level. The primary outcome is recurrence-free survival, as assessed by neck ultrasound every 6 to 12 months. Secondary endpoints include disease-free survival, overall survival, success rate in reaching the TSH target range, the proportion of patients with major cardiovascular diseases or bone metabolic disease, the quality of life, and medical costs. The follow-up period is 5 years. Conclusion The results of this trial will contribute to establishing the optimal indication for TSH suppression therapy in low-risk papillary thyroid cancer patients by evaluating the benefit and harm of lowering TSH levels in terms of recurrence, metabolic complications, costs, and quality of life. |
topic |
thyroid neoplasms thyrotropin thyroxine recurrence thyroidectomy |
url |
http://www.e-enm.org/upload/pdf/enm-2020-943.pdf |
work_keys_str_mv |
AT eunkyunglee amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT yeaeunkang amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT youngjoopark amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT bonseokkoo amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT kiwookchung amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT eujeongku amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT horyunwon amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT wonsangyoo amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT eonjujeon amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT sehyunpaek amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT yongsanglee amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT dongmeelim amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT yongjoonsuh amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT hakyoungpark amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT hyojeongkim amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT bohyunkim amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT mijinkim amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT sunwookkim amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT kaheeyi amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT suekpark amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT eunjaejung amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT juneyoungchoi amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT jaseongbae amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT joonhwahong amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT keehyunnam amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT youngkilee amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT hyeongwonyu amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT sujeonggo amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT youngmikang amulticenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT eunkyunglee multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT yeaeunkang multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT youngjoopark multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT bonseokkoo multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT kiwookchung multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT eujeongku multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT horyunwon multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT wonsangyoo multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT eonjujeon multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT sehyunpaek multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT yongsanglee multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT dongmeelim multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT yongjoonsuh multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT hakyoungpark multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT hyojeongkim multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT bohyunkim multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT mijinkim multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT sunwookkim multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT kaheeyi multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT suekpark multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT eunjaejung multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT juneyoungchoi multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT jaseongbae multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT joonhwahong multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT keehyunnam multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT youngkilee multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT hyeongwonyu multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT sujeonggo multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol AT youngmikang multicenterrandomizedcontrolledtrialforassessingtheusefulnessofsuppressingthyroidstimulatinghormonetargetlevelsafterthyroidlobectomyinlowtointermediateriskthyroidcancerpatientsmasterastudyprotocol |
_version_ |
1721318826896785408 |
spelling |
doaj-21d56038b3d5450bb69611762dcf6f102021-07-05T06:12:46ZengAcademya Publishing Co.Endocrinology and Metabolism2093-596X2093-59782021-06-0136357458110.3803/EnM.2020.9432165A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study ProtocolEun Kyung Lee0Yea Eun Kang1Young Joo Park2Bon Seok Koo3Ki-Wook Chung4Eu Jeong Ku5Ho-Ryun Won6Won Sang Yoo7Eonju Jeon8Se Hyun Paek9Yong Sang Lee10Dong Mee Lim11Yong Joon Suh12Ha Kyoung Park13Hyo-Jeong Kim14Bo Hyun Kim15Mijin Kim16Sun Wook Kim17Ka Hee Yi18Sue K. Park19Eun-Jae Jung20June Young Choi21Ja Seong Bae22Joon Hwa Hong23Kee-Hyun Nam24Young Ki Lee25Hyeong Won Yu26Sujeong Go27Young Mi Kang28 Center for Thyroid Cancer, National Cancer Center, Goyang, Korea Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea Department of Otorhinolaryngology-Head and Neck Surgery, Chungnam National University College of Medicine, Daejeon, Korea Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea Department of Otorhinolaryngology-Head and Neck Surgery, Chungnam National University College of Medicine, Daejeon, Korea Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea Department of Surgery, Ewha Womans University School of Medicine, Seoul, Korea Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea Department of Internal Medicine, Konyang University Hospital, Daejeon, Korea Department of Breast and Endocrine Surgery, Hallym University Sacred Heart Hospital, Anyang, Korea Department of Surgery, Inje University Busan Paik Hospital, Busan, Korea Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University, Seoul, Korea Department of Internal Medicine, Pusan National University Hospital, Busan, Korea Department of Internal Medicine, Pusan National University Hospital, Busan, Korea Division of Endocrinology & Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine, Seoul, Korea Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Korea Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea Department of Internal Medicine, Daejeon Eulji Medical Center, Eulji University, Daejeon, Korea Department of Surgery, Yonsei University College of Medicine, Seoul, Korea Center for Thyroid Cancer, National Cancer Center, Goyang, Korea Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Korea Center for Thyroid Cancer, National Cancer Center, Goyang, Korea Department of Otorhinolaryngology-Head and Neck Surgery, Chungnam National University College of Medicine, Daejeon, KoreaBackground Postoperative thyroid stimulating hormone (TSH) suppression therapy is recommended for patients with intermediate- and high-risk differentiated thyroid cancer to prevent the recurrence of thyroid cancer. With the recent increase in small thyroid cancer cases, the extent of resection during surgery has generally decreased. Therefore, questions have been raised about the efficacy and long-term side effects of TSH suppression therapy in patients who have undergone a lobectomy. Methods This is a multicenter, prospective, randomized, controlled clinical trial in which 2,986 patients with papillary thyroid cancer are randomized into a high-TSH group (intervention) and a low-TSH group (control) after having undergone a lobectomy. The principle of treatment includes a TSH-lowering regimen aimed at TSH levels between 0.3 and 1.99 μIU/mL in the low-TSH group. The high-TSH group targets TSH levels between 2.0 and 7.99 μIU/mL. The dose of levothyroxine will be adjusted at each visit to maintain the target TSH level. The primary outcome is recurrence-free survival, as assessed by neck ultrasound every 6 to 12 months. Secondary endpoints include disease-free survival, overall survival, success rate in reaching the TSH target range, the proportion of patients with major cardiovascular diseases or bone metabolic disease, the quality of life, and medical costs. The follow-up period is 5 years. Conclusion The results of this trial will contribute to establishing the optimal indication for TSH suppression therapy in low-risk papillary thyroid cancer patients by evaluating the benefit and harm of lowering TSH levels in terms of recurrence, metabolic complications, costs, and quality of life.http://www.e-enm.org/upload/pdf/enm-2020-943.pdfthyroid neoplasmsthyrotropinthyroxinerecurrencethyroidectomy |